文献速递前列腺癌

经会阴与经直肠磁共振成像靶向前列腺穿刺活检诊断前列腺癌:随机PERFECT试验(CCAFU-PR1)最终结果

Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1).
PubMed 文献 · Eur Urol Oncol · 2024-02-24

在这项非劣效性随机对照试验中,270例磁共振阳性且未活检过的患者按1:1随机接受经会阴或经直肠磁共振靶向穿刺。靶向穿刺检出有意义前列腺癌(ISUP≥2)的比例经会阴组为47.2%、经直肠组为54.2%(差值-7%,p=0.6235),未证实经会阴对经直肠的非劣效性。病灶位置影响穿刺途径的检出率。

要点

  • 经会阴与经直肠靶向穿刺检出有意义前列腺癌(ISUP≥2)比例分别为47.2%与54.2%,差值-7%,p=0.6235。
  • 后部病灶经直肠检出率更高(59.0% vs 44.3%,p=0.0443),前部病灶经会阴检出率更高(40.6% vs 26.5%,p=0.2228)。
  • 不良事件≥2级在经会阴组为35.7%、经直肠组为40.5%(p=0.4256),经直肠组1例(0.8%)发生3级脓毒症。

核心结论

  • 尽管两组任何级别前列腺癌总体检出率相当,但经会阴靶向穿刺对有意义前列腺癌检出的非劣效性未得到证实。
  • 磁共振病灶位置影响穿刺途径的表现,提示基于病灶位置的实用策略可能改善有意义前列腺癌的评估。

研究设计与样本

  • 非劣效性随机对照试验,按1:1随机分配270例磁共振阳性且未活检过的患者。
  • 干预为磁共振靶向前列腺穿刺,经会阴途径对比经直肠途径。

主要发现

  • 靶向穿刺检出有意义前列腺癌(ISUP≥2)的比例经会阴组为47.2%、经直肠组为54.2%(差值-7%,p=0.6235)。
  • 靶向穿刺任何级别前列腺癌检出率经会阴组为71.3%、经直肠组为64.1%(p=0.2209),经会阴组检出的ISUP 1病例显著更多。
  • 按病灶分析,后部病灶经直肠检出率为59.0%、经会阴为44.3%(p=0.0443);前部病灶经会阴检出率为40.6%、经直肠为26.5%(p=0.2228)。
  • 不良事件≥2级在经会阴组为35.7%、经直肠组为40.5%(p=0.4256);经直肠组1例(0.8%)发生3级脓毒症。
  • 生活质量、泌尿功能、性功能及疼痛评分两组相当。

临床怎么用

  • 作者认为,两种穿刺途径根据病灶位置似乎具有互补性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent guidelines favor transperineal (TP) prostate biopsies over the transrectal (TR) approach due to a reduced sepsis risk. Yet, evidence from controlled trial comparing both approaches within the MRI-targeted pathway for significant prostate cancer (PCa) detection is lacking. OBJECTIVE: To compare the significant PCa detection rate between magnetic resonance imaging (MRI)-targeted TR and TP approaches in biopsy-naïve patients. DESIGN, SETTING, AND PARTICIPANTS: In this noninferiority controlled trial, we randomized (ratio 1:1) 270 MRI-positive biopsy-naïve patients. INTERVENTION: MRI-targeted TP versus TR biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: The primary outcome was the detection rate of significant PCa (International Society of Urological Pathology [ISUP] ≥2) in MRI-targeted biopsies. Secondary outcomes were any-grade PCa detection, detection on concomitant systematic biopsy, complications, and functional outcomes. RESULTS AND LIMITATIONS: Targeted biopsies identified significant PCa in 47.2% of TP and 54.2% of TR participants (-7%, p = 0.6235). On a per-lesion analysis, posterior lesions yielded higher detection rates via TR (59.0% vs 44.3%, p = 0.0443), while anterior lesions were more frequently detected via TP (40.6% vs 26.5%, p = 0.2228). The overall (any grade) cancer detection rate in targeted biopsies was comparable between groups: 71.3% (TP) versus 64.1% (TR; p = 0.2209) with significantly more ISUP 1 cases detected in the TP arm. Adverse events of grade ≥2 were not different between TP (35.7%) and TR (40.5%, p = 0.4256). One TR patient (0.8%) experienced grade 3 sepsis. Quality of life, and urinary and sexual function, as well as pain scores, were comparable between groups. CONCLUSIONS: Despite a comparable overall detection rate for any-grade PCa, noninferiority of TP over TR for MRI-targeted biopsies for significant PCa detection was not demonstrated. However, MRI lesion location influenced biopsy route performance, suggesting that a pragmatic approach based on lesion location might enhance significant PCa assessment. PATIENT SUMMARY: This trial compared the efficacy and safety of two biopsy approaches for prostate cancer diagnosis. Both approaches seem complementary according to the lesion location.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Ploussard G, Barret E, Fiard G, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1). Eur Urol Oncol. 2024. PMID: 38403523. doi:10.1016/j.euo.2024.01.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。